SEC Form SC 13D/A filed by Hyperfine Inc. (Amendment)

SEC Form SC 13D/A filed by Hyperfine Inc. (Amendment)

Recent Analyst Ratings for $HYPR

$HYPR Market Insights

$HYPR SEC Filings

$HYPR Insider Trading

$HYPR Analyst Ratings

$HYPR Financials

$HYPR Press Releases

$HYPR Leadership Updates

$HYPR Large Ownership Changes

Recent Analyst Ratings for
$HYPR

$HYPR
Market Insights

$HYPR
SEC Filings

$HYPR
Insider Trading

$HYPR
Analyst Ratings

$HYPR
Financials

$HYPR
Press Releases

$HYPR
Leadership Updates

$HYPR
Large Ownership Changes

Chat with this insight

Live Market Insights

Hyperfine Announces FDA Clearance Of Software Update That Enables Faster Acquisition Of Best-In-Class Ultra-Low-Field Brain Images

Hyperfine's Portable MRI As Tissue Clock For Acute Ischemic Stroke: Multi-Site Study Published In August 2024 Edition Of Annals Of Neurology

Hyperfine's Clinical Research Using Swoop System For Alzheimer's Disease Monitoring To Be Presented At The 2024 Alzheimer's Association International Conference

SEC Form 10-Q filed by Hyperfine Inc.

Hyperfine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Hyperfine Inc.

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Operating Officer Teisseyre Thomas sold $2,380 worth of shares (2,800 units at $0.85), decreasing direct ownership by 3% to 88,227 units (SEC Form 4)

Chief Operating Officer Teisseyre Thomas sold $2,883 worth of shares (2,746 units at $1.05), decreasing direct ownership by 3% to 91,027 units (SEC Form 4)

SEC Form 4 filed by Director Rothberg Jonathan M

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Hyperfine downgraded by Wells Fargo with a new price target

Evercore ISI initiated coverage on Hyperfine with a new price target

Wells Fargo initiated coverage on Hyperfine with a new price target

Live finance-specific insights

Hyperfine, Inc. Reports Third Quarter 2024 Financial Results

Hyperfine, Inc. to Announce Third Quarter 2024 Financial Results on November 12, 2024

Hyperfine, Inc. Reports Record Quarterly Revenue and Raises FY 2024 Revenue Guidance

Fastest customizable press release news feed in the world

Hyperfine Swoop® Portable MR Brain Imaging System Meets New Standards Recently Issued by CMS-Approved Accrediting Body

Hyperfine Announces Ten Abstracts at RSNA, Highlighting the Expanding Utility and Potential of Portable MR Brain Imaging in Diverse Clinical and Research Settings

Hyperfine, Inc. to Participate in Upcoming Investor Conferences

Live Leadership Updates

Hyperfine, Inc. Continues Global Market Expansion by Entering Into a Distribution Partnership with Radiosurgery Global, Ltd. to Bring the Swoop® System to India

Hyperfine, Inc. to Expand Global Market Reach with Appointment of International Distributors in Key European Markets

22nd Century Appoints Larry Firestone as Chairman and CEO

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Hyperfine Inc.

SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

12/6/22 6:58:36 PM ET

$HYPR

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Get the next $HYPR alert in real time by email

SC 13D/A 1 d423465dsc13da.htm SC 13D/A (AMENDMENT NO.1) SC 13D/A (Amendment No.1)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Hyperfine, Inc.

(Name of Issuer)

Class A common stock, par value $0.0001 per share

Class B common stock, par value $0.0001 per share

(Title of Class of Securities)

Class A common stock: 44916K106

Class B common stock: Not Applicable

(CUSIP Number)

Jonathan M. Rothberg, Ph.D.

c/o Hyperfine, Inc.

351 New Whitfield Street

Guilford, Connecticut 06437

(866) 796-6767

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

Copies to:

Michael L. Fantozzi, Esq.

John P. Condon, Esq.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

One Financial Center

Boston, Massachusetts 02111

November 30, 2022

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


	SCHEDULE 13D
CUSIP NO. 74765K105	13D	Page 2 of 9


1		NAMES OF REPORTING PERSON Jonathan M. Rothberg, Ph.D.
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS PF¹
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION United States of America

Consists of (i) 104,074 shares of Class A common stock of Hyperfine, Inc. (f/k/a HealthCor Catalio Acquisition Corp.) (the “Issuer”) held by Jonathan M. Rothberg, Ph.D. and 762,047 shares of Class A common stock of the Issuer held by Jonathan M. Rothberg 2003 Revocable Trust, (ii) restricted stock units (“RSUs”) for 6,528 shares of Class A common stock of the Issuer, which vest within 60 days of November 30, 2022, held by Dr. Jonathan Rothberg, (iii) a stock option to purchase 982,500 shares of Class A common stock of the Issuer held by Dr. Jonathan Rothberg, (vi) 585,737 shares of Class A common stock of the Issuer held by 2012 JMR Trust Common, LLC, (v) 6,867,790 shares of Class B common stock of the Issuer held by 4C Holdings I, LLC, (vi) 7,368,748 shares of Class B common stock of the Issuer distributed from 4C Holdings I, LLC and held by entities owned by trusts created for the benefit of Dr. Jonathan Rothberg’s children, and (vii) 818,750 shares of Class B common stock of the Issuer held by 4C Holdings V, LLC.

²	Consists of (i) 440,295 shares of Class A common stock of the Issuer held by 23rd Century Capital LLC, and (ii) 95,507 shares of Class A common stock of the Issuer held by Dr. Jonathan Rothberg’s spouse, Bonnie E. Gould Rothberg, M.D.

³	Calculated based on 55,520,444 shares of Class A common stock of the Issuer and 15,055,288 shares of Class B common stock of the Issuer outstanding as of November 1, 2022, as reported in the Issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 10, 2022.


	SCHEDULE 13D
CUSIP NO. 74765K105	13D	Page 3 of 9


1		NAMES OF REPORTING PERSON 23rd Century Capital LLC
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS PF
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

⁴	Calculated based on 55,520,444 shares of Class A common stock of the Issuer outstanding as of November 1, 2022, as reported in the Issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 10, 2022.


	SCHEDULE 13D
CUSIP NO. 74765K105	13D	Page 4 of 9


1		NAMES OF REPORTING PERSON 2012 JMR Trust Common, LLC
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS PF
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

⁵	Calculated based on 55,520,444 shares of Class A common stock of the Issuer outstanding as of November 1, 2022, as reported in the Issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 10, 2022.


	SCHEDULE 13D
CUSIP NO. 74765K105	13D	Page 5 of 9


1		NAMES OF REPORTING PERSON 4C Holdings I, LLC
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS PF
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

⁶	Calculated based on 15,055,288 shares of Class B common stock of the Issuer outstanding as of November 1, 2022, as reported in the Issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 10, 2022.


	SCHEDULE 13D
CUSIP NO. 74765K105	13D	Page 6 of 9


1		NAMES OF REPORTING PERSON 4C Holdings V, LLC
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS PF
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

⁷	Calculated based on 15,055,288 shares of Class B common stock of the Issuer outstanding as of November 1, 2022, as reported in the Issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 10, 2022.


	SCHEDULE 13D
CUSIP NO. 74765K105	13D	Page 7 of 9

Explanatory Note

This Amendment No. 1 to Schedule 13D (“Amendment No. 1”) amends and supplements the Schedule 13D filed on December 30, 2021 (the “Schedule 13D”) relating to the Class A common stock, par value $0.0001 per share, and Class B common stock, par value $0.0001 per share, of Hyperfine, Inc. (f/k/a HealthCor Catalio Acquisition Corp.), a Delaware corporation (the “Issuer”). Information reported in the Schedule 13D remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment No. 1. Capitalized terms used but not defined herein have the meanings ascribed to them in the Schedule 13D.

Item 1. Security and Issuer.

There are no changes to the Item 1 information previously filed.

Item 2. Identity and Background.

Item 2 sections (c) and (f) of the Schedule 13D is hereby amended and restated in its entirety below:

(c) Dr. Jonathan Rothberg is the founder of Legacy Hyperfine (defined below) and a member of the Board of Directors of the Issuer. He is a member of 23rd Century Capital LLC, a trustee of the 2003 Jonathan M. Rothberg Revocable Trust, and is the sole manager of 2012 JMR Trust Common, LLC, 4C Holdings I, LLC, 4C Holdings V, LLC, and the limited liability company distributees of 4C Holdings I, LLC. Dr. Jonathan Rothberg is the founder of the 4Catalyzer medical technology incubator and the founder and Chairman of its companies.

(f) Dr. Jonathan Rothberg is a citizen of the United States of America. Each of 23rd Century Capital LLC, 2012 JMR Trust Common, LLC, 4C Holdings I, LLC, 4C Holdings V, LLC, and the limited liability company distributees of 4C Holdings I, LLC is a limited liability company organized under the laws of Delaware.

Item 3. Source and Amount of Funds or Other Consideration.

Item 3 of the Schedule 13D is hereby amended and supplemented by adding the following:

As set forth in Annex A, between June 14, 2022 and November 30, 2022, Dr. Jonathan Rothberg purchased an aggregate of 762,047 shares of Class A common stock of the Issuer in open market transactions.

Item 4. Purpose of Transaction.

Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following:

The information set forth in Item 3 above is incorporated into this Item 4 by reference.

Item 5. Interest in Securities of the Issuer.

Item 5 of the Schedule 13D is hereby amended and supplemented by adding the following:

The information set forth in Item 3 above is incorporated into this Item 5 by reference.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

There are no changes to the Item 6 information previously filed.

Item 7. Material to be Filed as Exhibits.

There are no changes to the Item 7 previously filed.


	SCHEDULE 13D
CUSIP NO. 74765K105	13D	Page 8 of 9

SIGNATURE

After reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.


Dated: December 6, 2022	/s/ Jonathan M. Rothberg
	Jonathan M. Rothberg, Ph.D.

	23rd Century Capital LLC
	By:	/s/ Jonathan M. Rothberg
	Name:	Jonathan M. Rothberg, Ph.D.
	Title:	Member

	2012 JMR Trust Common, LLC
	By:	/s/ Jonathan M. Rothberg
	Name:	Jonathan M. Rothberg, Ph.D.
	Title:	Manager

	4C Holdings I, LLC
	By:	/s/ Jonathan M. Rothberg
	Name:	Jonathan M. Rothberg, Ph.D.
	Title:	Manager

	4C Holdings V, LLC
	By:	/s/ Jonathan M. Rothberg
	Name:	Jonathan M. Rothberg, Ph.D.
	Title:	Manager

Annex A

Trading History

The following transactions were effected by Dr. Jonathan Rothberg in Class A common stock of the Issuer between June 14, 2022 and November 30, 2022:


Trade Date	Amount Purchased		Weighted Average Price Per Share
06/14/2022		52,848	$	2.26
08/12/2022		303,137	$	1.457
08/16/2022		64,213	$	1.482
11/14/2022		34,488	$	0.89
11/15/2022		31,139	$	0.92
11/29/2022		47,007	$	0.72
11/30/2022		229,215	$	0.82

Get the next $HYPR alert in real time by email

Date	Price Target	Rating	Analyst
8/11/2022	$8.00 → $2.40	Overweight → Equal Weight	Wells Fargo
5/31/2022	$7.00	Outperform	Evercore ISI
4/14/2022	$8.00	Overweight	Wells Fargo

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

SOLE VOTING POWER

2,440,886 shares of Class A common stock and 15,055,288 shares of Class B common stock¹

SHARED VOTING POWER

535,802 shares of Class A common stock²

SOLE DISPOSITIVE POWER

2,440,886 shares of Class A common stock and 15,055,288 shares of Class B common stock¹

SHARED DISPOSITIVE POWER

535,802 shares of Class A common stock²